(BVI) Bureau Veritas - Ratings and Ratios
Testing, Inspection, Certification, Laboratory Services, Auditing
Description: BVI Bureau Veritas
Bureau Veritas SA is a leading provider of laboratory testing, inspection, and certification services, operating through six key segments: Marine & Offshore, Agri-Food & Commodities, Industry, Buildings & Infrastructure, Certification, and Consumer Products. The company offers a comprehensive range of services, including inspection, analysis, auditing, and certification, to ensure compliance with regulatory or self-imposed standards across various industries.
With a global presence in approximately 140 countries, Bureau Veritas serves a diverse client base across construction, oil and gas, automotive, aerospace, and consumer products, among others. The companys extensive network of offices and laboratories enables it to provide technical services, testing, and certification to reduce risk, control quality, and verify quantity.
From a financial perspective, Bureau Veritas has demonstrated strong performance, with a Return on Equity (RoE) of 59.36%, indicating efficient use of shareholder capital. The companys Price-to-Earnings (P/E) ratio is 22.42, with a forward P/E of 19.53, suggesting a relatively stable earnings outlook. With a market capitalization of €12.42 billion, Bureau Veritas is a significant player in the Research & Consulting Services industry.
To further evaluate the companys prospects, key performance indicators (KPIs) such as revenue growth, operating margin, and cash flow generation can be monitored. Additionally, metrics like the debt-to-equity ratio and interest coverage can provide insights into Bureau Veritas financial health and leverage. A thorough analysis of these KPIs can help investors and stakeholders make informed decisions about the companys potential for future growth and returns.
BVI Stock Overview
| Market Cap in USD | 14,013m |
| Sub-Industry | Research & Consulting Services |
| IPO / Inception | 2007-10-24 |
BVI Stock Ratings
| Growth Rating | 15.8% |
| Fundamental | 83.8% |
| Dividend Rating | 68.6% |
| Return 12m vs S&P 500 | -21.9% |
| Analyst Rating | - |
BVI Dividends
| Dividend Yield 12m | 3.28% |
| Yield on Cost 5y | 5.18% |
| Annual Growth 5y | 23.22% |
| Payout Consistency | 88.6% |
| Payout Ratio | 62.1% |
BVI Growth Ratios
| Growth Correlation 3m | -82.8% |
| Growth Correlation 12m | -48.9% |
| Growth Correlation 5y | 69.8% |
| CAGR 5y | 8.32% |
| CAGR/Max DD 3y | 0.40 |
| CAGR/Mean DD 3y | 1.54 |
| Sharpe Ratio 12m | -0.22 |
| Alpha | -26.89 |
| Beta | 0.844 |
| Volatility | 17.64% |
| Current Volume | 1059.6k |
| Average Volume 20d | 665.2k |
| Stop Loss | 26 (-3.1%) |
| Signal | 1.36 |
Piotroski VR‑10 (Strict, 0-10) 8.5
| Net Income (1.16b TTM) > 0 and > 6% of Revenue (6% = 749.5m TTM) |
| FCFTA 0.23 (>2.0%) and ΔFCFTA 11.58pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 3.48% (prev 12.85%; Δ -9.37pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.28 (>3.0%) and CFO 1.82b > Net Income 1.16b (YES >=105%, WARN >=100%) |
| Net Debt (1.72b) to EBITDA (2.48b) ratio: 0.69 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.18 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (451.5m) change vs 12m ago -1.12% (target <= -2.0% for YES) |
| Gross Margin 48.41% (prev 32.59%; Δ 15.82pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 182.4% (prev 120.3%; Δ 62.14pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 9.22 (EBITDA TTM 2.48b / Interest Expense TTM 207.2m) >= 6 (WARN >= 3) |
Altman Z'' 3.54
| (A) 0.07 = (Total Current Assets 2.92b - Total Current Liabilities 2.48b) / Total Assets 6.56b |
| (B) 0.21 = Retained Earnings (Balance) 1.39b / Total Assets 6.56b |
| (C) 0.28 = EBIT TTM 1.91b / Avg Total Assets 6.85b |
| (D) 0.52 = Book Value of Equity 2.62b / Total Liabilities 5.08b |
| Total Rating: 3.54 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 83.79
| 1. Piotroski 8.50pt = 3.50 |
| 2. FCF Yield 11.51% = 5.0 |
| 3. FCF Margin 12.27% = 3.07 |
| 4. Debt/Equity 1.55 = 1.41 |
| 5. Debt/Ebitda 0.90 = 1.90 |
| 6. ROIC - WACC 22.89% = 12.50 |
| 7. RoE 66.64% = 2.50 |
| 8. Rev. Trend 51.97% = 2.60 |
| 9. Rev. CAGR 9.19% = 1.15 |
| 10. EPS Trend 6.58% = 0.16 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of BVI shares?
Over the past week, the price has changed by +0.83%, over one month by +0.00%, over three months by -5.46% and over the past year by -7.60%.
Is Bureau Veritas a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BVI is around 24.93 EUR . This means that BVI is currently overvalued and has a potential downside of -7.12%.
Is BVI a buy, sell or hold?
What are the forecasts/targets for the BVI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 33.9 | 26.4% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 27.7 | 3.2% |
BVI Fundamental Data Overview
Market Cap EUR = 11.95b (11.95b EUR * 1.0 EUR.EUR)
CCE Cash And Equivalents = 867.5m EUR (last quarter)
P/E Trailing = 18.5103
P/E Forward = 16.8919
P/S = 1.8047
P/B = 8.1586
P/EG = 2.1937
Beta = 0.734
Revenue TTM = 12.49b EUR
EBIT TTM = 1.91b EUR
EBITDA TTM = 2.48b EUR
Long Term Debt = 1.89b EUR (from longTermDebt, last quarter)
Short Term Debt = 341.4m EUR (from shortTermDebt, last quarter)
Debt = 2.23b EUR (Calculated: Short Term 341.4m + Long Term 1.89b)
Net Debt = 1.72b EUR (from netDebt column, last quarter)
Enterprise Value = 13.32b EUR (11.95b + Debt 2.23b - CCE 867.5m)
Interest Coverage Ratio = 9.22 (Ebit TTM 1.91b / Interest Expense TTM 207.2m)
FCF Yield = 11.51% (FCF TTM 1.53b / Enterprise Value 13.32b)
FCF Margin = 12.27% (FCF TTM 1.53b / Revenue TTM 12.49b)
Net Margin = 9.31% (Net Income TTM 1.16b / Revenue TTM 12.49b)
Gross Margin = 48.41% ((Revenue TTM 12.49b - Cost of Revenue TTM 6.44b) / Revenue TTM)
Tobins Q-Ratio = 5.08 (Enterprise Value 13.32b / Book Value Of Equity 2.62b)
Interest Expense / Debt = 1.83% (Interest Expense 40.8m / Debt 2.23b)
Taxrate = 31.73% (273.8m / 863.0m)
NOPAT = 1.30b (EBIT 1.91b * (1 - 31.73%))
Current Ratio = 1.18 (Total Current Assets 2.92b / Total Current Liabilities 2.48b)
Debt / Equity = 1.55 (Debt 2.23b / last Quarter total Stockholder Equity 1.44b)
Debt / EBITDA = 0.90 (Net Debt 1.72b / EBITDA 2.48b)
Debt / FCF = 1.46 (Debt 2.23b / FCF TTM 1.53b)
Total Stockholder Equity = 1.74b (last 4 quarters mean)
RoA = 17.73% (Net Income 1.16b, Total Assets 6.56b )
RoE = 66.64% (Net Income TTM 1.16b / Total Stockholder Equity 1.74b)
RoCE = 52.52% (Ebit 1.91b / (Equity 1.74b + L.T.Debt 1.89b))
RoIC = 30.78% (NOPAT 1.30b / Invested Capital 4.24b)
WACC = 7.89% (E(11.95b)/V(14.19b) * Re(9.13%)) + (D(2.23b)/V(14.19b) * Rd(1.83%) * (1-Tc(0.32)))
Shares Correlation 3-Years: -24.24 | Cagr: -0.05%
Discount Rate = 9.13% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 77.99% ; FCFE base≈1.26b ; Y1≈1.55b ; Y5≈2.64b
Fair Price DCF = 82.96 (DCF Value 36.80b / Shares Outstanding 443.6m; 5y FCF grow 25.0% → 3.0% )
Revenue Correlation: 51.97 | Revenue CAGR: 9.19%
Rev Growth-of-Growth: 25.10
EPS Correlation: 6.58 | EPS CAGR: 0.0%
EPS Growth-of-Growth: 159.6